NSL 96184
Latest Information Update: 27 Aug 2002
Price :
$50 *
At a glance
- Originator Nippon Steel
- Class Antiplatelets; Benzamidines; Piperidines; Small molecules; Thiazolidines; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 11 Mar 1999 New profile
- 11 Mar 1999 Preclinical development for Thrombosis in Japan (PO)